Candida auris is an emerging fungal pathogen gaining national attention—and for good reason. In this episode of Rounding@IOWA, Dr. Gerry Clancy sits down with infectious disease experts Dr. Karen Brust and Dr. Joseph Tholany to discuss why C. auris is so difficult to eliminate in healthcare settings, who is most at risk and why, the challenges of antifungal resistance, and practical steps clinicians can take to prevent spread. CME Credit Available: CE Credit Available Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Guests: Karen Brust, MD Hospital Epidemiologist, University of Iowa Health Care Clinical Associate Professor of Internal Medicine-Infectious Diseases University of Iowa Carver College of Medicine Joseph Tholany, MD Clinical Assistant Professor of Internal Medicine-Infectious Diseases University of Iowa Carver College of Medicine Financial Disclosures: Dr. Gerard Clancy, Dr. Karen Brust, Dr. Joseph Tholany, and Rounding@IOWA planning committee members have disclosed no relevant financial relationships. Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 1.0 ANCC contact hour. Pharmacist and Pharmacy Tech: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this knowledge-based activity for a maximum of 1.0 ACPE contact hours. Credit will be uploaded to the NABP CPE Monitor within 60 days after the activity completion. Pharmacists must provide their NABP ID and DOB (MMDD) to receive credit. JA0000310-0000-26-047-H01 Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.) References/Resources: Lionakis MS, Chowdhary A. Candida auris Infections. N Engl J Med. 2024;391(20):1924-1935. Doi:10.1056/NEJMra2402635 Casadevall A, et al. On the Emergence of Candida auris: Climate Change, Azoles, Swamps, and Birds. mBio. 2019;10(4):e01397-19. Published 2019 Jul 23. doi:10.1128/mBio.01397-19 Sharma C, Kadosh D. Perspective on the origin, resistance, and spread of the emerging human fungal pathogen Candida auris. PLoS Pathog. 2023;19(3):e1011190. Published 2023 Mar 23. doi:10.1371/journal.ppat.1011190 Dire O, et al. Survival of Candida auris on environmental surface materials and low-level resistance to disinfectant. J Hosp Infect. 2023;137:17-23. doi:10.1016/j.jhin.2023.04.007 Castanheira M, et al. Recent increase in Candida auris frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization. Antimicrob Agents Chemother. 2024;68(10):e0057024. doi:10.1128/aac.00570-24 Pacilli, Massimo, et al. "Regional emergence of Candida auris in Chicago and lessons learned from intensive follow-up at 1 ventilator-capable skilled nursing facility." Clinical Infectious Diseases 71.11 (2020): e718-e725 Rhodes, Johanna, and Matthew C. Fisher. "Global epidemiology of emerging Candida auris." Current opinion in microbiology 52 (2019): 84-89. https://www.cdc.gov/mmwr/volumes/74/wr/mm7425a1.htm